The tariff classification of a stationary oxygen concentrator from China
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- The applicable subheading for the IntenOxy 5 Stationary Oxygen Concentrator will be 9019.20.0000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “[o]zone therapy, oxygen therapy, aerosol therapy, artificial respiration or other therapeutic respiration apparatus; parts and accessories thereof.” The rate of duty will be free.
Ruling text
In your letter dated March 10, 2025, you requested a tariff classification ruling on behalf of your client, Caire Inc. The product under consideration is the IntenOxy 5 Stationary Oxygen Concentrator for hospital or home use. It has a top handle, a plastic housing, and four wheels on the bottom. The top of the device has three control buttons and an oxygen outlet. The front of the plastic housing features a display panel, a flowmeter, and a flowmeter knob.
The oxygen concentrator measures 15.35 inches x 9.65 inches x 19.69 inches (W x D x H) and weighs 34.2 lbs. The product is intended as an oxygen supplement device (for adults only) in a professional healthcare facility and/or a home healthcare environment. It provides a high concentration of oxygen to persons requiring oxygen therapy by pulling in and compressing the ambient air, then separating nitrogen from the air to provide purified oxygen for breathing to the end user.
The oxygen concentration provides an oxygen flow rate of 0.5 - 5 L/min with an oxygen concentration level between 95.5 percent – 87 percent and has a minimum operating time of 15 minutes. You state that the device is specifically designed for the treatment of chronic respiratory conditions (such as COPD, pulmonary fibrosis, and other chronic lung diseases and disorders).
It is only available with a doctor’s prescription and the item is distributed directly by Caire Inc. or by health care distributors that have authority to provide prescription-based products.
The applicable subheading for the IntenOxy 5 Stationary Oxygen Concentrator will be 9019.20.0000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “[o]zone therapy, oxygen therapy, aerosol therapy, artificial respiration or other therapeutic respiration apparatus; parts and accessories thereof.” The rate of duty will be free.
Effective March 4, 2025, pursuant to U.S. Note 2(u) to Subchapter III, Chapter 99, all products of China and Hong Kong as provided by heading 9903.01.24, HTSUS, other than products classifiable under headings 9903.01.21, 9903.01.22, and 9903.01.23, HTSUS, will be subject to an additional 20 percent ad valorem rate of duty. At the time of entry, you must report the applicable Chapter 99 heading, i.e. 9903.01.24, in addition to subheading 9019.20.0000, HTSUS, listed above.
However, the additional duties imposed by heading 9903.01.24 shall not apply to goods for which entry is properly claimed under a provision of chapter 98 of the tariff schedule pursuant to applicable regulations of U.S. Customs and Border Protection (“CBP”), and whenever CBP agrees that entry under such a provision is appropriate, except for goods entered under heading 9802.00.80; and subheadings 9802.00.40, 9802.00.50, and 9802.00.60.
For subheadings 9802.00.40, 9802.00.50, and 9802.00.60, the additional duties apply to the value of repairs, alterations, or processing performed (in China and Hong Kong), as described in the applicable subheading. For heading 9802.00.80, the additional duties apply to the value of the article assembled abroad (in China and Hong Kong), less the cost or value of such products of the United States, as described.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N346597).